secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2024-04-08T23:59:59+00:00
Accession:  0001193125-24-089164
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics appoints Chrystal U. Louis as CMO; Dr. Debora Barton departs
-------------------------------------------------------------------------------

- Chrystal U. Louis, M.D., M.P.H., named Chief Medical Officer effective April 8, 2024.
- Dr. Louis brings 20+ years of hematology/oncology drug development and cell therapy experience.
- Outgoing CMO Dr. Debora Barton departing for personal reasons; will continue as consultant.
- Dr. Barton joined TScan in July 2022; contributed to heme program and solid tumor initiation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312524089164/0001193125-24-089164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312524089164/d810490d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-089164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer